Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Performance

52-Week Range 60.3% below 52-week high

1.390

1.0552W Low 3.5052W High

1 Week 11.5% below 1-week high

1.361W Low 1.571W High

Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB) traded between $1.05 and $3.50 over the past 52 weeks and last traded at $1.39, 60.3% below its 52-week high. Over the past week it ranged between $1.36 and $1.57.

Past 12 Months

-0.7%

-43.3%

-15.8%

-18.2%

-22.3%

-58.6%

1W -$0.01

1M -$1.06

3M -$0.26

6M -$0.31

YTD -$0.40

1Y -$1.97

CMMB was -58.6% over the past year, -18.2% over six months, -22.3% year to date, -0.7% in the last week.

12 Months vs Market

CMMB

-58.6%

DIA

+12.4%

SPY

+17.4%

QQQ

+23.9%

IWM

+13.7%

Over the past 12 months CMMB returned -58.6% versus DIA (Dow) +12.4%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +23.9% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.00× 3-mo avg

Today 3 3-mo avg 109.4K

17.1K

139.6K

109.4K

112.5K

YTD

98.1K

101.5K

CMMB most recently traded 3 shares against a 3-month average daily volume of 109.4K.

More News

August 19, 2026

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

July 09, 2026

Via Chartmill

July 08, 2026

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

11 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 02, 2026

Via Benzinga

May 14, 2026

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

March 19, 2026

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

December 02, 2025

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

November 24, 2025

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

November 20, 2025

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

November 06, 2025

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

August 21, 2025

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 19, 2025

Via Benzinga

August 14, 2025

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

June 30, 2025

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

June 11, 2025

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

June 03, 2025

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

May 05, 2025

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

April 28, 2025

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

April 21, 2025

Chemomab Announces New Medical and Clinical Appointments

April 15, 2025